The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

Today’s health headlines: ketamine nasal sprays offer a new option for people with treatment-resistant depression. Plus, how ...

Researchers at the Kazakh National Agrarian Research University have developed a pioneering nasal treatment for hay fever ...

Milestone Pharmaceuticals (NASDAQ:MIST) announced on Friday that the U.S. FDA accepted for review its responses to the rejection letter sent early this year regarding its marketing application for its ...